Aromasin Exemestane PCT An Overview

This review describes the development of AIs and their current use in breast cancer. Recent research focuses on elucidating mechanisms of acquired resistance that may develop in some patients with long term AI treatment and also on innate resistance. Preclinical data in resistance models demonstrated that the crosstalk between ER and other signaling pathways particularly MAPK and PI3K/Akt is an important resistant mechanism. Blockade of these other signaling pathways is an attractive strategy to circumvent the resistance to AI therapy in breast cancer. Due to the potential negative effect on cholesterol, Aromasin and other AI’s should only be used when necessary.

These steroids can cause an increase in prolactin, which is considered a female hormone. Side effects that are similar to estrogenic side effects but which you need to tackle differently to how you deal with estrogen-related adverse effects. To do this, you can follow the estrogen control measures I’ve shared relating to gyno and other estrogenic side effects – this will ensure your estrogen levels remain healthy. Again, it’s all about halting the rise of estrogen levels, but do so without excessive AI doses (if those are your drugs of choice). It’s known that AIs can be detrimental to your skin quality at higher doses. Though Gynectrol is not limited to on-cycle use, its benefits go beyond being an anti-gyno formula.

So, while Arimidex does have some testosterone-stimulating ability, it is not considered to be strong enough to combat very low testosterone, which is why it’s not often included in PCT cycles. We can get used to the most common ancillary drugs being very cheap to buy. But Arimidex is quite expensive, and on a per-tablet basis, you’ll pay a lot more for this AI than we do for most SERMs. Other uncommon possible side effects of Arimidex include fatigue, headache, nausea, and hot flashes. Still, once again, these are almost always only seen in women who use Arimidex for long periods. Yes, many of the signs of low estrogen are similar to those of low testosterone!

• Combinations of the new aromatase inhibitors with LHRH agonists are therefore now being prospectively studied.
• This also helps with reducing any negative impacts on your cholesterol.
• Nonetheless, this cross-talk between ER and these 2 major signaling pathways appears to be a dynamic interface.
• In a 3-week protocol, one of the recommended dosages is to take 100mg on the first day, followed by 60mg for 10 days, then drop to 40mg for the final 10 days.
• A phase II study also addressed the activity of exemestane after failure of a nonsteroidal aromatase inhibitor.33 In a study of 242 patients, 44% had received aminoglutethimide and 56%, another aromatase inhibitor.

Aromatase and Its Inhibitors

Aromasin is an aromatase inhibitor, so it lowers your entire estrogen levels, and gyno is caused by the excess estrogen when you’re using aromatizing steroids like testosterone and derivatives of testosterone like Dianabol (Dbol). Because Aromasin is so effective at lowering estrogen, possibly as low as 85%, it should work well to prevent or at least greatly minimize the risk of gyno. This is short for anti-estrogen, which are also sometimes called estrogen antagonists or estrogen blockers. Anti-E is simply a more common term used to describe the various SERMs and aromatase inhibitors we use during PCT to lower estrogen and increase testosterone production.

It was further demonstrated that 4-OH-A could reduce estrogen concentrations which resulted in tumor regression in rat mammary tumors. Also, 4-OH-A appeared to be more effective than tamoxifen without the adverse estrogenic effect on other tissue particularly the uterus 13. Given that the aromatase enzyme has a very specific function in the steroid biosynthesis, selective aromatase inhibition is truly a targeted approach for breast cancer treatment that confers only minimal side effects. In the past decade, multiple clinical trials have not only demonstrated a superior efficacy of AIs over tamoxifen, but also better side effect profile of these agents.

Product categories

Current AIs can be classified into two subtypes, namely steroidal and non-steroidal AIs (Table 1). Given that some the AIs have steroid-like structure similar to the aromatase substrate, androstenedione, this subtype of AIs has been termed steroidal AIs or type I inhibitor. Due to its similarity, these AIs bind to the substrate-binding site of aromatase enzyme. After binding, they are converted to a reactive intermediate that covalently bind to the enzyme causing irreversible inaction. These inhibitors are also known as “suicide inhibitor” because the enzyme is inactivated by its own function 17, 18. For type II inhibitor or non-steroidal AIs, these AIs bind non-covalently to the heme moiety of the aromatase enzyme and prevent binding of androgens by saturating the binding-site.

However, this effect is not as strong as in the case of strongly androgenic steroids such as trenbolone. In a few cases methenolone can lower the libido – this is due to the fact that it has a slight anti-estrogenic effect. For this reason it should be used in combination with steroids that convert to estrogen.

In a therapeutic setting, by blocking the aromatase enzyme, Aromasin actively prohibits the cancer from feeding off the hormone necessary to its survival. It has been proven highly effective for this purpose, but only after the use of the Selective Estrogen Receptor Modulator (SERM) Nolvadex (Tamoxifen Citrate) has failed. This simple yet very potent compound called Arimistane® will have users experiencing all of the benefits from an increase in testosterone and the reduction of high levels of estrogen and cortisol.

Nonetheless, this cross-talk between ER and these 2 major signaling pathways appears to be a dynamic interface. Using the similar model, we found that interrupting letrozole treatment can reverse tumors into their baseline state. There are significant increases in ERα and aromatase expression levels as well as a reduction in phosphorylated MAPK to the similar levels at baseline. These changes after interrupting the treatment also restore the sensitivity to AIs. At 22 weeks, after LTLT-Ca (letrozole resistant) xenograft tumors have become resistant to letrozole, a short interruption of letrozole for 6 weeks can induce regress of tumors again after resuming letrozole treatment 96, 104.

Due to these unfavorable side effects and incomplete blockade of estrogen action, the alternative approach to target the ligand production instead of the ER itself was hypothesized to be more effective with fewer side effects. They reported the first series of these compounds in 1973 11 with the hope of blocking the production of estrogen with specific inhibitors of ECA aromatase 11–13. 4-hydroxy-androstenedione (4-OH-A) was demonstrated to be the most potent aromatase inhibitor of more than 100 compounds either synthesized or acquired for testing 13, 14. Subsequently, this compound was found to act by rapid competitive inhibition as well as inactivation of the enzyme resulting in long lasting or irreversible effect 15.